NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Expert to Discuss Supply Strategies at Upcoming Clinical Outsourcing Group Conference
Catalent today announced that its Global Director of Clinical Supply Management, Stephanie Graham, is to speak at the upcoming Clinical Outsourcing Group Conference, to be held in London, U.K., on Feb. 21-22, 2023.
Catalent Completes Expansion of Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities
The project has seen the site increase by approximately 30,000 square feet, which has allowed the installation of additional refrigerated and deep-frozen storage, and secondary packaging capabilities to be expanded.
New Drug, TASCENSO ODT® (Fingolimod), Launched
The launch ensures MS patients in the US currently benefitting from Gilenya, or generic fingolimod, can access appropriate patient support services alongside the bioequivalent, non-generic, TASCENSO ODT.
Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary
Joseph A. Ferraro joins Catalent as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary in February 2023 and is responsible for managing Catalent’s global legal and compliance operations.
Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium
The state-of-the-art facility contains development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply
Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies
The new Case Management Service addresses challenges associated with delivering advanced therapies to patients by providing supply chain oversight from program start to finish.
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
Mr. Zayas will be responsible for Catalent’s North American biologics operations. He will serve on the Executive Leadership Team, reporting directly to President & CEO, Alessandro Maselli.
Catalent and Ethicann Sign Agreement for New Cannabinoid-Based Treatments
Catalent and Ethicann announced a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet technology.
Sarepta and Catalent Expand Strategic Manufacturing Partnership
Catalent and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.
RDD Europe 2023
Date: May 2-5, 2023
Exploring a One-Stop Integrated Solution for AAV Vector Clinical Production
Date: May 3, 2023
Achieving Desired Particle Size and Yield Through Efficient Micronization
Date: May 9, 2023
Clinical Trial Supply West Coast 2023
Date: May 9-10, 2023
Vitafoods Europe 2023
Date: May 9-11, 2023
PEGS Boston 2023
Date: May 15-19, 2023
2023 Global Drug Bioavailability Enhancement Summit
Date: May 16-17, 2023
2023 Controlled & Modified Drug Release Summit
Date: May 16-17, 2023
ASGCT 26th Annual Meeting
Date: May 16-20, 2023
ALS Drug Development Summit
Date: May 16-18, 2023
ATS 2023 Respiratory Innovation Summit
Date: May 19-20, 2023
5th Annual Allogeneic Cell Therapies Summit
Date: May 22-25, 2023
Clinical Trial Supply Forum 2023
Date: May 23-25, 2023
ISCT 2023 Paris Annual Meeting
Date: May 31 – June 3, 2023
2023 BIO International Convention
Date: June 5-8, 2023
ISSCR 2023 Annual Meeting
Date: June 14-17, 2023
DIA China 2023
Date: June 16-19, 2023